<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091206</url>
  </required_header>
  <id_info>
    <org_study_id>GWEP1332 Part A</org_study_id>
    <nct_id>NCT02091206</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)</brief_title>
  <official_title>A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Research Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Research Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics of multiple doses of GWP42003-P compared with
      placebo in children with Dravet syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center study will consist of two parts: Part A and Part B. Part A only will be
      described in this record. Part A is a randomized, double blind 21-day treatment study period.
      Subjects will be randomized to one of three doses of active or placebo at a 4:1 ratio.

      Subjects who satisfy all inclusion and none of the exclusion criteria will be assigned a
      unique participant number and then begin a 28-day baseline observation period.

      Eligible subjects will then be randomly assigned to receive one of three dose levels of
      GWP42003-P: 5 mg/kg, 10 mg/kg or 20 mg/kg per day, or matching placebo.

      There will be three groups of 10 subjects. In each group, subjects will be randomly assigned
      so that eight subjects receive active treatment and two subjects receive placebo. Subjects
      will receive GWP42003-P or placebo for a 21-day exposure period, which consists of a
      titration period, followed by a stable dose period.

      A pharmacokinetic assessment will take place after the first single dose of GWP42003-P. There
      will be a second pharmacokinetic assessment after 21 days of consecutive dosing with
      GWP42003-P. Subjects who take clobazam as an adjunctive treatment will be asked to take their
      usual dose two hours prior to attending the clinic. The same recommendation will be made for
      other concomitant antiepileptic drugs, if applicable. This is so that the pre-treatment (with
      GWP42003-P) plasma concentrations of clobazam, its major metabolite N-desmethylclobazam, and
      any other concomitant antiepileptic drugs can be measured, and the impact of GWP42003-P
      treatment on these levels evaluated. Interim clinic visits to (primarily) evaluate safety and
      adherence to the titration regimen will take place at seven and 14 days of treatment.

      After 21 days of treatment, all subjects will commence a 10-day down-titration taper period.
      An independent Data Safety Monitoring Committee will review unblinded safety and
      pharmacokinetic data and recommend the target dose (up to 20 mg/kg/day) for Part B of the
      study and for an open label extension study. Once the safety review of Part A data has taken
      place, subjects will have the option of entering the open label extension study.

      A follow-up telephone call will be made 28 days after the end of dosing for subjects who do
      not enter the open label extension study within this time-frame.

      Throughout the 21-day treatment period and the 10-day taper period, there will be regular
      safety telephone calls (i.e., approximately every two days) to check subject status. Weekly
      safety telephone calls will be made during the 28-day follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events as measure of subject safety</measure>
    <time_frame>Day -28 to Day 60</time_frame>
    <description>The number of subjects who experienced an adverse event during the study is presented. The time frame for adverse event reporting was from screening to the Part A follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The plasma concentration time curves for cannabidiol and its major metabolite following single and multiple doses of GWP42003-P</measure>
    <time_frame>Pre-dose then 2-3 and 4-6 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of clobazam and N-desmethylclobazam, if taken concomitantly with GWP42003-P, prior to single and multiple doses of GWP42003-P</measure>
    <time_frame>Pre-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Epilepsy</condition>
  <condition>Dravet Syndrome</condition>
  <arm_group>
    <arm_group_label>Group/dose level 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg/day GWP42003-P oral solution. All subjects will down-titrate (10% per day) over a 10-day period following 21 days of treatment or withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/dose level 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg/day GWP42003-P oral solution. All subjects will down-titrate (10% per day) over a 10-day period following 21 days of treatment or withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/dose level 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg/day GWP42003-P oral solution. All subjects will down-titrate (10% per day) over a 10-day period following 21 days of treatment or withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/dose level 1b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for Group/dose level 1a.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/dose level 2b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for Group/dose level 2a.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/dose level 3b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for Group/dose level 3a.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GWP42003-P</intervention_name>
    <description>GWP42003-P is an oral solution presented as an oily solution containing 25 mg/mL cannabidiol (CBD: FT0086) or 100 mg/mL CBD (FT0095) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Subjects will be randomly assigned to receive either 5, 10 or 20 mg/kg/day.</description>
    <arm_group_label>Group/dose level 1a</arm_group_label>
    <arm_group_label>Group/dose level 2a</arm_group_label>
    <arm_group_label>Group/dose level 3a</arm_group_label>
    <other_name>Cannabidiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.</description>
    <arm_group_label>Group/dose level 1b</arm_group_label>
    <arm_group_label>Group/dose level 2b</arm_group_label>
    <arm_group_label>Group/dose level 3b</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject must be male or female aged between four and 10 years (inclusive).

          -  Subject must have a documented history of Dravet syndrome which is not completely
             controlled by current antiepileptic drugs.

          -  Subject must be taking one or more antiepileptic drugs at a dose which has been stable
             for at least four weeks.

          -  All medications or interventions for epilepsy (including ketogenic diet and vagus
             nerve stimulation) must have been stable for four weeks prior to screening and subject
             is willing to maintain a stable regimen throughout the study.

        Key Exclusion Criteria:

          -  Subject has clinically significant unstable medical conditions other than epilepsy.

          -  Subject has had clinically relevant symptoms or a clinically significant illness in
             the four weeks prior to screening or randomization, other than epilepsy.

          -  Subject is currently using or has in the past used recreational or medicinal cannabis,
             or synthetic cannabinoid based medications (including SativexÂ®) within the three
             months prior to study entry and is unwilling to abstain for the duration for the
             study.

          -  Subject has any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the investigational medicinal products.

          -  Subjects who have been part of a clinical trial involving another investigational
             product in the previous six months.

          -  There are plans for the subject to travel outside their country of residence during
             the study.

          -  Subjects previously randomized into this study. In particular, subjects participating
             in Part A of the study cannot enter Part B.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <disposition_first_submitted>June 17, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 21, 2016</disposition_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

